GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » ROE % Adjusted to Book Value

Mega Genomics (HKSE:06667) ROE % Adjusted to Book Value : 3.42% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics ROE % Adjusted to Book Value?

Mega Genomics's ROE % for the quarter that ended in Jun. 2024 was 11.22%. Mega Genomics's PB Ratio for the quarter that ended in Jun. 2024 was 3.28. Mega Genomics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 3.42%.

Mega Genomics ROE % Adjusted to Book Value Historical Data

The historical data trend for Mega Genomics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics ROE % Adjusted to Book Value Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Negative Equity - - -0.57 1.36

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only 0.93 -2.42 3.20 -0.45 3.42

Competitive Comparison of Mega Genomics's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Mega Genomics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Genomics's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Mega Genomics's ROE % Adjusted to Book Value falls into.


Mega Genomics ROE % Adjusted to Book Value Calculation

Mega Genomics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=4.71% / 3.47
=1.36%

Mega Genomics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.22% / 3.28
=3.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mega Genomics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Mega Genomics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
HKSE:09960 HKSE:02325 HKSE:08037 HKSE:02427 HKSE:08225 HKSE:08247 HKSE:00928 HKSE:09860 TMO DHR XSWX:LONN A IDXX IQV SHSE:603259 MTD WAT NTRA LH DGX
Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Website
https://www.megagenomics.cn
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Dongyin Industrial (shenzhen) Co., Ltd. 2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd. 2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership) 2106 Person having a security interest in shares
Yurong Technology Limited 2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd. 2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited 2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership) 2106 Person having a security interest in shares
Guo Meiling 2101 Beneficial owner
Yu Rong 2501 Other
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other

Mega Genomics Headlines

No Headlines